Collegium Pharmaceutical, Inc. (COLL) News
Follow Collegium Pharmaceutical, Inc. (COLL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Collegium Pharmaceutical reports quarterly results
Collegium Pharmaceutical reported results for the quarter ended September 30. The alert does not provide financial figures.
EQUITY | Nov 05, 2026, 03:09 PM UTC
M
Collegium Pharmaceutical Reports Q3 2026 Results, Reaffirms Guidance
Quarterly net revenue reached a record $216.3 million and adjusted EBITDA was $121.6 million. JORNAY PM revenue rose 24% year over year to $51.9 million; AZSTARYS revenue was $26.5 million.
EQUITY | Nov 05, 2026, 02:04 PM UTC
M
Collegium Pharmaceutical Q3 earnings snapshot
EQUITY | Nov 05, 2026, 12:51 PM UTC
M
Collegium Reports Q3 2026 Results, Reaffirms Guidance
Collegium reported third-quarter 2026 financial results and reaffirmed its 2026 guidance. Quarterly net revenue was $216.3 million, up 3% year over year.
EQUITY | Nov 05, 2026, 12:44 PM UTC
M
Collegium Pharmaceutical Reports Third-Quarter Revenue of $216.34 Million
Collegium Pharmaceutical’s product revenues rose as higher Jornay PM sales and the addition of Azstarys more than offset declines in Nucynta, Xtampza ER, Belbuca and Symproic. Net income fell amid higher selling, general
EQUITY | Nov 05, 2026, 12:43 PM UTC
M
Collegium Affirms FY2026 Sales Guidance of $825M-$855M
Collegium Pharmaceutical affirmed FY2026 sales guidance of $825.000M-$855.000M, versus an estimate of $835.780M.
EARNINGS | Nov 05, 2026, 12:37 PM UTC
M
Collegium Ends Grünenthal Nucynta U.S. License in $17 Million Settlement
Collegium Pharmaceutical and Grünenthal settled disputes related to Nucynta, including pending patent litigation over the authorized generic for Nucynta ER. They mutually terminated their 2015 U.S. License Agreement.
EQUITY | Oct 19, 2026, 08:13 PM UTC
H
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript
Collegium Pharmaceutical (NASDAQ: COLL ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered APIs. For comprehensive financial da
LIVE | Oct 05, 2026, 10:29 AM UTC
L
Collegium Pharmaceutical Price Target Announced at $50.00/Share by Oppenheimer
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 11:09 AM UTC
L
Truist maintains Buy on Collegium Pharmaceutical; cuts price target to $49
Truist Securities maintained a Buy on Collegium Pharmaceutical and cut its price target to $49.00 per share from $58.00, per Benzinga/TradingView.
EQUITY | Sep 09, 2026, 04:26 PM UTC
L
Collegium Pharmaceutical price target set at $45 by Leerink
Leerink Partners announced a $45.00/share price target for Collegium Pharmaceutical.
EQUITY | Sep 09, 2026, 03:26 PM UTC
L
Collegium management to participate in upcoming investor conferences
Collegium Pharmaceutical, Inc. said management will participate in upcoming investor conferences, according to a company announcement.
EQUITY | Sep 08, 2026, 12:07 PM UTC
L
COLL - Collegium to Participate in Upcoming Investor Conferences
COLL - Collegium to Participate in Upcoming Investor Conferences
EQUITY | Sep 08, 2026, 12:00 PM UTC
M
Collegium announces $50 million accelerated share repurchase program
Collegium (COLL) announces a $50 million accelerated share repurchase program.
EQUITY | Aug 13, 2026, 11:30 AM UTC
L
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est
Collegium Pharmaceutical (NASDAQ: COLL ) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.
EARNINGS | Aug 06, 2026, 11:31 AM UTC
L
COLL - Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
COLL - Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
EARNINGS | Aug 06, 2026, 11:30 AM UTC